Stocks

SPARC may shine on Sun Pharma royalty

| Updated on January 11, 2019 Published on January 11, 2019

Sun Pharma has made a milestone payment of $10 million to Sun Pharma Advanced Research Company as royalty for Xelprostm. Sun Pharma had earlier said it had received US FDA approval for Xelprostm, which is indicated for the treatment of open-angle glaucoma or ocular hypertension. Sun Pharma, which had in-licensed Xelprostm from Sun Pharma Advanced Research Company in 2015, has commercialised the product. The royalty payment is linked to sales.

Published on January 11, 2019
This article is closed for comments.
Please Email the Editor